First patient dosed in phase 2 trial with Imugene’s gastric cancer vaccine
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced dosing of the first patient in a in 68 patient randomised Phase 2 HER-Vaxx cancer trial.
HER-Vaxx is a potentially ground-breaking cancer vaccine designed to produce an antibody response against a cancer growth signal receptor protein called HER-2 which is found on the cell surface of multiple cancers including breast and gastic cancers.
The open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients saw the first patient dosed at the Oncological Institute in Chisinau, the capital of Moldova, in Eastern Europe.
This latest trial is being conducted at multiple sites across Asia, Eastern Europe and India where patients have difficulty accessing approved antibody treatments such as Herceptin and Perjeta marketed by Swiss multinational Roche Holding AG. There is also a high prevalence of gastric cancer in the countries selected.
Two Eastern European sites are now actively recruiting patients, with approval imminent for trial sites in Hong Kong, Taiwan, Thailand and India.
The Phase 2 study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein. It is randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of care alone.
The primary endpoint is overall survival and secondary endpoint will be progression-free survival. Safety, tolerability and immune response will also be measured.
The prior Phase 1b HER-Vaxx study reported no safety or toxicity issues, while all evaluable patients showed increased antibody responses. One patient saw a complete response, five had a partial response and four recorded a stabilisation of their disease.
Imugene Managing Director and Chief Executive Officer Leslie Chong said, “There is strong medical investigator interest following the good results seen in the recently completed Phase 1b trial, where 11 out of 14 evaluable patients showed clinically meaningful responses. We look forward to providing regular recruitment updates as the Phase 2 study moves toward completion in 2020.”
“The start of the Phase 2 study is an important milestone for Imugene and the many medical professionals seeking treatments for patients with advanced HER-2 positive gastric cancer who often have very few medical options.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
